Search

Your search keyword '"GalaGen Inc. -- Product development"' showing total 6 results
Start Over Descriptor "GalaGen Inc. -- Product development"
6 results on '"GalaGen Inc. -- Product development"'

1. How push-pull has affected four foods

Author

Pszczola, Donald E.

Subjects
Ocean Spray Cranberries Inc. -- International trade, ShanStar Biotech Inc. -- Product development, Strauss Veal -- Product development, Northland Cranberries Inc. -- Product development, National Starch and Chemical Co. -- Product development, GalaGen Inc. -- Product development, Dannon Company Inc. -- Product development, DCV Inc. -- Product development, Ingman Foods Oy AB -- Product development, BioGaia Biologics A.B. -- Product development, Swissland Packing co. -- Product development, Food industry -- Product development, Cranberries -- Supply and demand, Fruit industry -- Supply and demand, Veal -- Product development, Egg industry -- Product development, Dairy industry -- Product development, Gelatin -- Usage, Starch -- Usage, Biological products industry -- Product development, Functional foods -- Product development, Business, Food and beverage industries
Abstract

Technology push and marketing pull, the 'Find a need and fill it' concept, and their interplay are discussed in relation to product development involving cranberries, eggs, yogurt and veal. In each of these products some new developments have been made based both on technological advances and on the needs consumers perceive, largely related to health issues.

Published
1999

2. GALAGEN'S SPORIDIN-G QUALIFIES FOR ORPHAN DRUG DESIGNATION

Subjects
GalaGen Inc. -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

ARDEN HILLS, Md., March 17 /PRNewswire/ -- GalaGen Inc., a Minnesota-based biopharmaceutical firm, received notification from the Food and Drug Administration (FDA) that its product Sporidin-G qualifies for orphan designation, [...]

Published
1994

3. C O R R E C T I O N -- GALAGEN

Subjects
GalaGen Inc. -- Product development, Business, News, opinion and commentary
Abstract

In DC038, GalaGen's Sporidin-G Qualifies for Orphan Drug Designation, moved earlier today, we are advised by a representative for the company that the dateline should read 'ARDEN HILLS, Minn.' rather [...]

Published
1994

4. NEWLY FORMED GALAGEN INC. TO DEVELOP BIOPHARMACEUTICALS FROM MILK

Subjects
GalaGen Inc. -- Product development, Pharmaceutical industry -- Product development, Business, News, opinion and commentary
Abstract

NEWLY FORMED GALAGEN INC. TO DEVELOP BIOPHARMACEUTICALS FROM MILK Products to Prevent Secondary Infections in Immunocompromised Patients ST. PAUL, Minn., Aug. 10 /PRNewswire/ -- GalaGen Inc., a newly formed biotechnology [...]

Published
1992

5. Orphan status for Galagen's Sporidin-G

Subjects
United States. Food and Drug Administration -- Laws, regulations and rules, GalaGen Inc. -- Product development, Orphan drugs -- Product development, Pharmaceutical industry -- Product development, Cryptosporidiosis -- Drug therapy, AIDS (Disease) -- Complications, Anti-infective agents -- Product development, Business, Pharmaceuticals and cosmetics industries
Published
1994

6. GalaGen's Sporidin-G qualifies for orphan drug designation

Subjects
GalaGen Inc. -- Product development, Orphan drugs -- Product development, Cryptosporidiosis -- Drug therapy
Abstract

Pharmaceutical Update GalaGen Inc., a Minnesota-based biopharmaceutical firm, received notification from the U.S. Food and Drug Administration (FDA) that its product Sporidin-G qualifies for orphan designation, it was announced by [...]

Published
1994

Catalog

Books, media, physical & digital resources
See catalog results